az23 Search Results


az 23  (MuseChem Chemicals)
N/A
AZ-23(CAT:I003398) is an ATP-competitive and orally bioavailable inhibitor of tropomyosin receptor kinases (TrkA, TrkB, and TrkC) with high potency. It inhibits TrkA and TrkB with IC₅₀ values of 2 nM and 8 nM, respectively, while
   Buy from Supplier
az-23  (MedChemExpress)
N/A
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck),
   Buy from Supplier
osimertinib  (Alomone Labs)
92
Alomone Labs osimertinib
Fig. 3 MRAS and HEG1 are highly expressed in <t>osimertinib-resistant</t> cells and tissues. A The Venn plot of DEGs from the merged dataset and six datasets. B The heatmap of MRAS and HEG1 in osimertinib-sensitive and resistant LUAD cells from six GEO datasets. C Bare mean of counts of MRAS and HEG1 from the online RNA-seq data [9]. D IHC analysis of MRAS in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). E IHC analysis of HEG1 in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). F-G The Kaplan–Meier plots of the survival analysis of LUAD patient data from the GSE14814 dataset (N = 265)
Osimertinib, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/az23/pm39560891-152-0-13?v=Alomone+Labs
Average 92 stars, based on 1 article reviews
osimertinib - by Bioz Stars, 2026-08
92/100 stars
  Buy from Supplier
az-23  (Axon Medchem LLC)
90
Axon Medchem LLC az-23
Fig. 3 MRAS and HEG1 are highly expressed in <t>osimertinib-resistant</t> cells and tissues. A The Venn plot of DEGs from the merged dataset and six datasets. B The heatmap of MRAS and HEG1 in osimertinib-sensitive and resistant LUAD cells from six GEO datasets. C Bare mean of counts of MRAS and HEG1 from the online RNA-seq data [9]. D IHC analysis of MRAS in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). E IHC analysis of HEG1 in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). F-G The Kaplan–Meier plots of the survival analysis of LUAD patient data from the GSE14814 dataset (N = 265)
Az 23, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/az23/pmc06604814-297-29-32?v=Axon+Medchem+LLC
Average 90 stars, based on 1 article reviews
az-23 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
az-23  (AstraZeneca ltd)
90
AstraZeneca ltd az-23
Fig. 3 MRAS and HEG1 are highly expressed in <t>osimertinib-resistant</t> cells and tissues. A The Venn plot of DEGs from the merged dataset and six datasets. B The heatmap of MRAS and HEG1 in osimertinib-sensitive and resistant LUAD cells from six GEO datasets. C Bare mean of counts of MRAS and HEG1 from the online RNA-seq data [9]. D IHC analysis of MRAS in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). E IHC analysis of HEG1 in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). F-G The Kaplan–Meier plots of the survival analysis of LUAD patient data from the GSE14814 dataset (N = 265)
Az 23, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/az23/10__1158_slash_1078___0432__ccr___08___0651-124-43-38?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
az-23 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
az 23  (Biosynth Carbosynth)
N/A
Inhibitor of TrkA and TrkB kinases. Inhibitor of TrkA and TrkB kinases.
   Buy from Supplier
az-23  (TargetMol)
N/A
   Buy from Supplier
az-23  (Aladdin Scientific Corporation)
N/A
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC 50 s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99
   Buy from Supplier
az 23  (BOC Sciences)
N/A
AZ 23 is a potent and selective tyrosine kinase (Trk) inhibitor with the potential for therapeutic utility in neuroblastoma and multiple other cancer indications.
   Buy from Supplier

Image Search Results


Fig. 3 MRAS and HEG1 are highly expressed in osimertinib-resistant cells and tissues. A The Venn plot of DEGs from the merged dataset and six datasets. B The heatmap of MRAS and HEG1 in osimertinib-sensitive and resistant LUAD cells from six GEO datasets. C Bare mean of counts of MRAS and HEG1 from the online RNA-seq data [9]. D IHC analysis of MRAS in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). E IHC analysis of HEG1 in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). F-G The Kaplan–Meier plots of the survival analysis of LUAD patient data from the GSE14814 dataset (N = 265)

Journal: Discover oncology

Article Title: Aberrant expression of MRAS and HEG1 as the biomarkers for osimertinib resistance in LUAD.

doi: 10.1007/s12672-024-01552-6

Figure Lengend Snippet: Fig. 3 MRAS and HEG1 are highly expressed in osimertinib-resistant cells and tissues. A The Venn plot of DEGs from the merged dataset and six datasets. B The heatmap of MRAS and HEG1 in osimertinib-sensitive and resistant LUAD cells from six GEO datasets. C Bare mean of counts of MRAS and HEG1 from the online RNA-seq data [9]. D IHC analysis of MRAS in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). E IHC analysis of HEG1 in tumor biopsies from LUAD patients (left panel). The DAB positive signals were analyzed by the Halo data analysis system (right panel). F-G The Kaplan–Meier plots of the survival analysis of LUAD patient data from the GSE14814 dataset (N = 265)

Article Snippet: Osimertinib (Cat. S7297) and AZD1332 (Cat. A-495) were purchased from Selleck (USA) and Alomone Labs Vol:. (1234567890) (Israel), respectively.

Techniques: RNA Sequencing